TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01774409

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~* 1 tube for the constitutional DNA extraction;~* 3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board.
Study: NCT02759367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High potassium diet
Description: An increase in consumption of high potassium fruits and vegetables
Study: NCT02496052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Foley balloon
Description: Device: Foley balloon Uterine application of Foley balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley balloon
Description: Device: Foley balloon Uterine application of Foley balloon

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: estradiol valerate tablets+dydrogesterone Tablets
Description: oral estradiol valerate tablets+dydrogesterone Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets+dydrogesterone Tablets
Description: oral estradiol valerate tablets+dydrogesterone Tablets
Study: NCT04483648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
Study: NCT04120519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide combined with dexamethasone and cyclophosphamide
Description: TCD
Study: NCT01821560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00530504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device
Description: Carotid artery stenting with distal embolic protection.
Study: NCT00620503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg formulation A
Description: One Proellex 25 mg formulation A capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg formulation B
Description: One 25 mg Proellex capsule formulation B administered both fed and fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg formulation B
Description: One 25 mg Proellex capsule formulation B administered both fed and fasted
Study: NCT03254511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable
Description: Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapeutic Combinations
Description: Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic Combinations
Description: Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
Study: NCT03204240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
Study: NCT03719196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading glass
Description: Participants from the experimental group have received reading glasses free of cost. Investigators hypothesize that a simple pair of eyeglasses could improve the lives of these people by enabling continued participation in the workforce, restoring productivity levels in both paid and unpaid work, and enhancing the ability to perform everyday tasks. Investigators also hypothesize that reading glasses will improve quality of life.
Study: NCT01525225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release (IR)
Description: Tablet, Oral, 1000 mg, twice daily, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablet, Oral, 5 mg, single-dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Tablet, Oral, 1000 mg, twice daily, 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin XR FDC
Description: Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablet, Oral, 500 mg, Single-dose of 4 tablets
Study: NCT04408781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge expansion by osseodensifcation/Ridge expansion by ridge splitting
Description: Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge expansion by osseodensifcation/Ridge expansion by ridge splitting
Description: Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
Study: NCT00167219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Transplantation on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen
Description: * Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)
Study: NCT01305798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduling and Active Choice for Biometric Participation
Description: The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduling and Active Choice for Biometric Participation
Description: The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduling and Active Choice for Biometric Participation
Description: The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
Study: 31266030

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at 2 mA for 15 minutes over the left dorsolateral prefrontal cortex (F3) for 10 consecutive sessions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 8
Study: 28944595

Group type: EXPERIMENTAL
Intervention: TAU plus ECHOMANTRA
Number of subjects: 380

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 380
Study: 25924549

Group type: EXPERIMENTAL
Intervention: Modified therapy with tacrolimus and mycophenolate mofetil (steroid-free regimen)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard regimen with tacrolimus and steroids
Number of subjects: 117
Study: 23140129

Group type: EXPERIMENTAL
Intervention: Cervical TDR (Bryan Disc or Kineflex|C)
Number of subjects: 74

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 74
Study: 22458064

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction
Number of subjects: 0
Study: 19210527

Group type: EXPERIMENTAL
Intervention: CNI treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: CNI-avoidance
Number of subjects: 44
Study: 16784469

Group type: EXPERIMENTAL
Intervention: Transanal stent
Number of subjects: 194

Group type: COMPARATOR
Intervention: No transanal stent
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Transanal stent with ileostomy
Number of subjects: 194

Group type: COMPARATOR
Intervention: No transanal stent with ileostomy
Number of subjects: 194
Study: 15599776

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Psychosocial support (PST)
Number of subjects: 21
Study: 10906099

Group type: EXPERIMENTAL
Intervention: Examination with pharmacological mydriasis
Number of subjects: 173

Group type: COMPARATOR
Intervention: Examination without pharmacological mydriasis
Number of subjects: 173
Study: 9124477

Group type: EXPERIMENTAL
Intervention: Saline infusion (1.5 liter over 21 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LBNP+Saline infusion (1.5 liter with lower body negative pressure for 3 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no infusion or LBNP)
Number of subjects: 8
Study: 8312826

Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine (AZT) and dideoxycytidine (ddC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Monotherapy with zidovudine (AZT) alone
Number of subjects: 85

Group type: COMPARATOR
Intervention: Monotherapy with zidovudine (AZT)
Number of subjects: 85
Study: 3789208

Group type: EXPERIMENTAL
Intervention: transitional treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: control treatment
Number of subjects: 79
Study: 31517806

Group type: EXPERIMENTAL
Intervention: Swab self-collection method
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Tampon self-collection method
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard clinical method
Number of subjects: 174
Study: 28784554

Group type: EXPERIMENTAL
Intervention: Ab interno gelatin stent (XEN 45 Gel Stent)
Number of subjects: 65
Study: 26762247

Group type: EXPERIMENTAL
Intervention: Intraoral PBM treatment with an LED device (OrthoPulse™, Biolux Research Ltd.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (orthodontic treatment only)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intraoral PBM treatment
Number of subjects: 19
Study: 24232132

Group type: EXPERIMENTAL
Intervention: Prepped vaginal canal insertion of Atrium Prolite mesh (polypropylene monofilament)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laparoscopic trocar-site insertion of mesh
Number of subjects: 10
Study: 23084379

Group type: EXPERIMENTAL
Intervention: Eyes that developed type 1 ROP
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination of venular width and arteriolar tortuosity
Number of subjects: 41

Group type: COMPARATOR
Intervention: Eyes that did not develop type 1 ROP
Number of subjects: 41
Study: 19202152

Group type: EXPERIMENTAL
Intervention: Oseltamivir (antiviral agent)
Number of subjects: 0
Study: 17688919

Group type: EXPERIMENTAL
Intervention: Continuing low-dose aspirin (LDA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Replacing LDA with low-molecular-weight heparin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Discontinuing low-dose aspirin (LDA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 200
Study: 15184213

Group type: EXPERIMENTAL
Intervention: Ibuprofen (4-10 mg/kg)
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Ibuprofen (5-10 mg/kg)
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Ibuprofen and acetaminophen
Number of subjects: 1820
Study: 11166775

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 53
Study: 9482142

Group type: EXPERIMENTAL
Intervention: 240 mg sustained release verapamil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 mg diltiazem
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8302501

Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 64

Group type: COMPARATOR
Intervention: Reference test evaluations
Number of subjects: 64
Study: 2657215

Group type: EXPERIMENTAL
Intervention: Hypothiaside
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 135
Study: 30570153

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no SR)
Number of subjects: 13
Study: 27802233

Group type: EXPERIMENTAL
Intervention: Multimodal Cognitive Enhancement Therapy (MCET)
Number of subjects: 64

Group type: COMPARATOR
Intervention: mock-therapy (placebo)
Number of subjects: 64
Study: 25864279

Group type: EXPERIMENTAL
Intervention: HSH40
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 40
Study: 24005873

Group type: EXPERIMENTAL
Intervention: Tensional loading (cast for 2 weeks and then a removable foam walker boot for 5 weeks, with special training pedal for predetermined, gradually increasing tensional load)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (cast immobilization for 7 weeks)
Number of subjects: 35
Study: 21347782

Group type: EXPERIMENTAL
Intervention: Preoperative RCT (50.4 Gy and concomitant either 5-FU or 5-FU and oxaliplatin)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Postoperative RCT
Number of subjects: 208

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 208
Study: 19858812

Group type: EXPERIMENTAL
Intervention: Interprofessional team care (primary care internal medicine residents, nurse practitioner students, pharmacy students)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual care (internal medicine residents only)
Number of subjects: 384
Study: 17826451

Group type: EXPERIMENTAL
Intervention: Function-centered treatment (FCT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Pain-centered treatment (PCT)
Number of subjects: 174
Study: 15165926

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 79

Group type: COMPARATOR
Intervention: No Isoproterenol (standard therapy)
Number of subjects: 79
Study: 14718901

Group type: EXPERIMENTAL
Intervention: AV-fistula group (AVFG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 59
Study: 10537439

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7497671

Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 103

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 103
Study: 2202559

Group type: EXPERIMENTAL
Intervention: Self-Monitoring at home
Number of subjects: 13006

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13006
Study: 7016286

Group type: EXPERIMENTAL
Intervention: Anterior mediastinum and posterior pericardium drainage (group 2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Only anterior mediastinum drainage (group 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 49
Study: 30342066

Group type: EXPERIMENTAL
Intervention: Goal-directed process EFT (Study 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Goal-directed process EFT (Study 2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: EFT general (Study 2)
Number of subjects: 57

Group type: COMPARATOR
Intervention: ERT control (Study 2)
Number of subjects: 57
Study: 30464426

Group type: EXPERIMENTAL
Intervention: Passive finger exercises (25 minutes daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 40
Study: 26216753

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 114
Study: 24873986

Group type: EXPERIMENTAL
Intervention: JEV + PCECV + MenACWY‐CRM
Number of subjects: 100

Group type: COMPARATOR
Intervention: JEV + PCECV
Number of subjects: 100

Group type: COMPARATOR
Intervention: MenACWY‐CRM
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCECV
Number of subjects: 100
Study: 22943949

Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone (group B)
Number of subjects: 62
Study: 20196970

Group type: EXPERIMENTAL
Intervention: 225 g of cold water prawns
Number of subjects: 23

Group type: COMPARATOR
Intervention: Equivalent weight of fish ('crab') sticks
Number of subjects: 23
Study: 17524566

Group type: EXPERIMENTAL
Intervention: Alcohol Urge Questionnaire
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Obsessive‐Compulsive Drinking Scale
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Penn Alcohol Craving Scale
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Temptation‐Restraint Inventory
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (need, urge, craving, desire, compulsion)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 112
Study: 16223391

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.4 microg/kg/min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12140024

Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure during Goldmann applanation tonometry in NTG eyes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure during Tono-pen XL in NTG eyes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure during Goldmann applanation tonometry in HTG eyes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure during Tono-pen XL in HTG eyes
Number of subjects: 40
Study: 9917801

Group type: EXPERIMENTAL
Intervention: Continuous active technician supervision
Number of subjects: 200

Group type: COMPARATOR
Intervention: No supervision after the initial 2 minutes of the test
Number of subjects: 200
Study: 7751527

Group type: EXPERIMENTAL
Intervention: Intranasal ipratropium bromide (0.03%, 0.06%, and 0.12% dosage strengths); 2 sprays per nostril (total dose of 84, 168, and 336 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal ipratropium bromide (0.03% and 0.06% dosage strengths) in patients with perennial rhinitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal ipratropium bromide (0.06% dosage strength) in patients with the common cold
Number of subjects: 0
Study: 31621252

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination therapy (Electroacupuncture + PNF)
Number of subjects: 96
Study: 28544507

Group type: EXPERIMENTAL
Intervention: Music with binaural beat technology (BBT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Music only
Number of subjects: 74
Study: 25703961

Group type: EXPERIMENTAL
Intervention: Riociguat up to 2.5 mg 3 times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat up to 1.5 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23174368

Group type: EXPERIMENTAL
Intervention: Extended release (ER) niacin (1500 mg per day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21615866

Group type: EXPERIMENTAL
Intervention: Leukosan(®) SkinLink
Number of subjects: 61

Group type: COMPARATOR
Intervention: Prolene suture
Number of subjects: 61
Study: 19932790

Group type: EXPERIMENTAL
Intervention: Anterior-lateral (A-L) electrode position
Number of subjects: 96

Group type: COMPARATOR
Intervention: Anterior-posterior (A-P) electrode position
Number of subjects: 96
Study: 16967401

Group type: EXPERIMENTAL
Intervention: Massage intervention with standard nursing care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with standard nursing care only
Number of subjects: 60